ScripThe hopes of spring may be returning to the South Korean biotech industry after a series of encouraging developments in recent months has more than made up for some other disappointing news, with prog
ScripWhile global pharma firms are rolling out advanced gene and cell therapies, as well as aggressively making R&D investments in the space to grab the leading position in the burgeoning market, South Kor
ScripHelixmith Co., Ltd. is set to use a new formulation of Engensis (VM202) for an upcoming Phase III trial for diabetic peripheral neuropathy (DPN), a move that may bring the company closer to commercia
Pink SheetUpcoming gene therapies for diabetic neuropathy, osteoarthritis and wet age-related macular degeneration are on track for launch in the US within the next three years and have expected patient populat